{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:55:17Z","timestamp":1792601717538,"version":"4.5.0"},"reference-count":80,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Treatment of locally advanced rectal cancer (LARC) very often requires a neoadjuvant multimodal approach. Neoadjuvant treatment (NAT) encompasses treatments like chemoradiotherapy (CRT), short-course radiotherapy (SCRT), radiotherapy (RT) or a combination of either of these two with additional induction or consolidation chemotherapy, namely total neoadjuvant treatment (TNT). In case of complete radiological and clinical response, the non-operative watch-and-wait strategy can be adopted in selected patients. This strategy is impacted by a regrowth rate of approximately 30%. Predicting biomarkers of tumor response to NAT could improve guidance of clinicians during clinical decision making, improving treatment outcomes and decreasing unnecessary treatment exposure. To this day, there is no validated biomarker to predict tumor response to any NAT strategies in clinical use. Most research focused on CRT neglects the study of other regimens. Methods: We conducted a narrative literature review which aimed at summarizing the status of biomarkers predicting tumor response to NAT other than CRT in LARC. Results: Two hundred and fourteen articles were identified. After screening, twenty-one full-text articles were included. Statistically significant markers associated with improved tumor response pre-treatment were as follows: low circulating CEA levels; BCL-2 expression; high cellular expression of Ku70, MIB-1(Ki-67) and EGFR; low cellular expression of VEGF, hPEBP4 and nuclear \u03b2-catenin; the absence of TP53, SMAD4, KRAS and LRP1B mutations; the presence of the G-allel of LCS-6; and MRI features such as the conventional biexponential fitting pseudodiffusion (Dp) mean value and standard deviation (SD), the variable projection Dp mean value and lymph node characteristics (short axis, smooth contour, homogeneity and Zhang et al. radiomic score). In the interval post-treatment and before surgery, significant markers were as follows: a reduction in the median value of circulating free DNA, higher presence of monocytic myeloid-derived suppressor cells, lower presence of CTLA4+ or PD1+ regulatory T cells and standardized index of shape changes on MRI. Conclusions: Responders to neoadjuvant SCRT and RT tended to have a tumor microenvironment with an immune\u2013active phenotype, whereas responders to TNT tended to have a less active tumor profile. Although some biomarkers hold great promise, scarce publications, inconsistent results, low statistical power, and low reproducibility prevent them from reliably predicting tumor response following NAT.<\/jats:p>","DOI":"10.3390\/cancers17132229","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:07:17Z","timestamp":1751515637000},"page":"2229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Narrative Review: Predictive Biomarkers of Tumor Response to Neoadjuvant Radiotherapy or Total Neoadjuvant Therapy of Locally Advanced Rectal Cancer Patients"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7210-4683","authenticated-orcid":false,"given":"Joao Victor","family":"Machado Carvalho","sequence":"first","affiliation":[{"name":"Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man, 1005 Lausanne, Switzerland"},{"name":"Department of Oncology, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Digestive Surgery, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-6101","authenticated-orcid":false,"given":"Frederic","family":"Ris","sequence":"additional","affiliation":[{"name":"Division of Digestive Surgery, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-0301","authenticated-orcid":false,"given":"Andr\u00e9","family":"Durham","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals of Geneva, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bornand","sequence":"additional","affiliation":[{"name":"Pathology Department, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-8428","authenticated-orcid":false,"given":"Alexis","family":"Ricoeur","sequence":"additional","affiliation":[{"name":"Service of Radiology, Geneva University Hospital, 1211 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-3667","authenticated-orcid":false,"given":"Claudia","family":"Corr\u00f2","sequence":"additional","affiliation":[{"name":"Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man, 1005 Lausanne, Switzerland"},{"name":"Department of Oncology, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9196-9076","authenticated-orcid":false,"given":"Thibaud","family":"Koessler","sequence":"additional","affiliation":[{"name":"Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man, 1005 Lausanne, Switzerland"},{"name":"Department of Oncology, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","first-page":"iv22","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Wyrwicz","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejca.2017.07.015","article-title":"Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study","volume":"84","author":"Minicozzi","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","article-title":"Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_6","first-page":"45","article-title":"Total Neoadjuvant Therapy for High Risk Rectal Cancer in Western and Asian Populations\u2014Current Evidence and Clinical Applications","volume":"21","author":"Johnson","year":"2022","journal-title":"Clin. Color. Cancer"},{"key":"ref_7","first-page":"231","article-title":"Evolving Treatment Options and Future Directions for Locally Advanced Rectal Cancer","volume":"18","author":"Chen","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103885","DOI":"10.1016\/j.critrevonc.2022.103885","article-title":"Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review","volume":"181","author":"He","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14737159.2018.1514258","article-title":"Clinical and molecular diagnosis of pathologic complete response in rectal cancer: An update","volume":"18","author":"Timmerman","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clon.2015.11.003","article-title":"Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer","volume":"28","author":"Gollins","year":"2016","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.clon.2022.12.006","article-title":"STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot","volume":"35","author":"Bach","year":"2023","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Smolskas, E., Mikulskyte, G., Sileika, E., Suziedelis, K., and Dulskas, A. (2022). Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116040"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s11864-023-01125-9","article-title":"The Crying Need for a Better Response Assessment in Rectal Cancer","volume":"24","author":"Amintas","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Machado Carvalho, J.V., Dutoit, V., Corro, C., and Koessler, T. (2023). Promises and Challenges of Predictive Blood Biomarkers for Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. Cells, 12.","DOI":"10.3390\/cells12030413"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103991","DOI":"10.1016\/j.critrevonc.2023.103991","article-title":"Predictive biomarkers in radioresistant rectal cancer: A systematic review","volume":"186","author":"Slipsager","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1007\/s00261-018-1801-z","article-title":"Diffusion and perfusion MR parameters to assess preoperative short-course radiotherapy response in locally advanced rectal cancer: A comparative explorative study among Standardized Index of Shape by DCE-MRI, intravoxel incoherent motion- and diffusion kurtosis imaging-derived parameters","volume":"44","author":"Fusco","year":"2019","journal-title":"Abdom. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1007\/s11605-011-1589-4","article-title":"Gender-related differences in repopulation and early tumor response to preoperative radiotherapy in rectal cancer patients","volume":"15","author":"Gasinska","year":"2011","journal-title":"J. Gastrointest. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s11605-014-2526-0","article-title":"Gender-related differences in pathological and clinical tumor response based on immunohistochemical proteins expression in rectal cancer patients treated with short course of preoperative radiotherapy","volume":"18","author":"Gasinska","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ho, V., Chung, L., Singh, A., Lea, V., Abubakar, A., Lim, S.H., Ng, W., Lee, M., de Souza, P., and Shin, J.S. (2018). Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4776-9"},{"key":"ref_20","first-page":"9","article-title":"Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy","volume":"36","author":"Truelsen","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.3748\/wjg.v19.i40.6876","article-title":"Overexpression of nuclear beta-catenin in rectal adenocarcinoma is associated with radioresistance","volume":"19","author":"Wang","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.18632\/oncotarget.3014","article-title":"Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients","volume":"6","author":"Napolitano","year":"2015","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00000658-200204000-00006","article-title":"TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer","volume":"235","author":"Kandioler","year":"2002","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjc.6604131","article-title":"Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy","volume":"98","author":"Negri","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00384-012-1534-3","article-title":"hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy","volume":"28","author":"Qiu","year":"2013","journal-title":"Int. J. Color. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ijc.10480","article-title":"Prognostic value of P53 mutations in rectal carcinoma","volume":"100","author":"Rebischung","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10350-004-6524-2","article-title":"p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy","volume":"46","author":"Saw","year":"2003","journal-title":"Dis. Colon Rectum"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/codi.12354","article-title":"Prognostic value of pretreatment level of carcinoembryonic antigen on tumour downstaging and early occurring metastasis in locally advanced rectal cancer following neoadjuvant radiotherapy (30 Gy in 10 fractions)","volume":"16","author":"Wang","year":"2014","journal-title":"Color. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/DCR.0000000000000107","article-title":"Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: A potential biomarker predictive of metastasis","volume":"57","author":"Yao","year":"2014","journal-title":"Dis. Colon Rectum"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.bjc.6604172","article-title":"Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy","volume":"98","author":"Zlobec","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/DCR.0000000000002245","article-title":"Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy","volume":"66","author":"Chapman","year":"2023","journal-title":"Dis. Colon Rectum"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Iseas, S., Sendoya, J.M., Robbio, J., Coraglio, M., Kujaruk, M., Mikolaitis, V., Rizzolo, M., Cabanne, A., Ruiz, G., and Salanova, R. (2021). Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.801880"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/annonc\/mdv285","article-title":"Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial","volume":"26","author":"Sclafani","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-20-4769","article-title":"Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial","volume":"27","author":"Vidal","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ijrobp.2023.05.027","article-title":"Development and Validation of a Radiomics Model Based on Lymph-Node Regression Grading After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer","volume":"117","author":"Zhang","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstrom","year":"1999","journal-title":"Semin. Cancer Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","article-title":"Circulating tumour cells in cancer patients: Challenges and perspectives","volume":"16","author":"Pantel","year":"2010","journal-title":"Trends Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1515\/cclm-2018-0610","article-title":"Liquid biopsy: Novel technologies and clinical applications","volume":"57","author":"Reimers","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbamcr.2015.10.022","article-title":"Characterization of the cell-free DNA released by cultured cancer cells","volume":"1863","author":"Bronkhorst","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_41","first-page":"181","article-title":"Circulating nucleic acids (CNAs) and cancer--a survey","volume":"1775","author":"Fleischhacker","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1158\/1541-7786.MCR-16-0044","article-title":"Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies","volume":"14","author":"Volik","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5.1.1","DOI":"10.1002\/cpim.40","article-title":"Flow Cytometry: An Overview","volume":"120","author":"McKinnon","year":"2018","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/39.6.1709656","article-title":"Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections","volume":"39","author":"Shi","year":"1991","journal-title":"J. Histochem. Cytochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: Attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.","DOI":"10.3390\/cancers13112748"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1158\/1078-0432.CCR-05-0879","article-title":"Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest","volume":"11","author":"Wang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12957-016-0977-3","article-title":"Effect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cells","volume":"14","author":"Qiu","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2019.01.011","article-title":"Ki-67 protein as a tumour proliferation marker","volume":"491","author":"Menon","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eadh3409","DOI":"10.1126\/sciadv.adh3409","article-title":"Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome","volume":"10","author":"Pandey","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sanchez-Canteli, M., Juesas, L., Garmendia, I., Otero-Rosales, M., Calvo, A., Alvarez-Fernandez, M., Astudillo, A., Montuenga, L.M., Garcia-Pedrero, J.M., and Rodrigo, J.P. (2022). Tumor-Intrinsic Nuclear beta-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911559"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Li, X., Xiang, Y., Li, F., Yin, C., Li, B., and Ke, X. (2019). WNT\/beta-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02293"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: Molecular mechanisms and interventional targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","article-title":"What is next generation sequencing?","volume":"98","author":"Behjati","year":"2013","journal-title":"Arch. Dis. Child. Educ. Pract. Ed."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2159-8290.CD-14-1118","article-title":"Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors","volume":"5","author":"Dienstmann","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hernandez Borrero, L.J., and El-Deiry, W.S. (2021). Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim. Biophys. Acta Rev. Cancer, 1876.","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/OTT.S297855","article-title":"Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells","volume":"14","author":"Wan","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2011.39.6036","article-title":"Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)","volume":"30","author":"Dewdney","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-14-0069","article-title":"Association study of the let-7 miRNA-complementary site variant in the 3\u2032 untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial)","volume":"20","author":"Sha","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Principe, C., Dionisio de Sousa, I.J., Prazeres, H., Soares, P., and Lima, R.T. (2021). LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090836"},{"key":"ref_63","first-page":"97","article-title":"Radiomic biomarkers of tumor immune biology and immunotherapy response","volume":"28","author":"Wang","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1148\/rg.2021210037","article-title":"Radiomics in Oncology: A Practical Guide","volume":"41","author":"Shur","year":"2021","journal-title":"Radiographics"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bourbonne, V., Schick, U., Pradier, O., Visvikis, D., Metges, J.P., and Badic, B. (2023). Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time?. Cancers, 15.","DOI":"10.3390\/cancers15020432"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1186\/s12967-024-05747-x","article-title":"Tumor microenvironment remodeling after neoadjuvant chemoradiotherapy in local advanced rectal cancer revealed by single-cell RNA sequencing","volume":"22","author":"Su","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-22-1125","article-title":"Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer","volume":"28","author":"Vayrynen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cpt.2023.07.003","article-title":"Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer","volume":"2","author":"Feng","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"ref_72","first-page":"e164","article-title":"The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response","volume":"19","author":"Chen","year":"2020","journal-title":"Clin. Color. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Orhan, A., Khesrawi, F., Tvilling Madsen, M., Peuliche Vogelsang, R., Dohrn, N., Kanstrup Fiehn, A.M., and Gogenur, I. (2022). Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14030636"},{"key":"ref_75","first-page":"26","article-title":"ASCO highlights: Neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer","volume":"18","author":"Piringer","year":"2025","journal-title":"Mag. Eur. Med. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","article-title":"Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-20-0337","article-title":"A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy","volume":"26","author":"Kirilovsky","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.30461","article-title":"Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States","volume":"123","author":"Mowery","year":"2017","journal-title":"Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199103143241101","article-title":"Effective surgical adjuvant therapy for high-risk rectal carcinoma","volume":"324","author":"Krook","year":"1991","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:35Z","timestamp":1760033015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":80,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132229"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132229","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}